Valsartan is orally active, and specific angiotensin II antagonist acting on the AT1 receptor subtype (angiotensin receptor blocker). It is a lipophilic in nature and is feebly aqueous soluble drug with absolute bioavailability of 25%. The goal of the present study was to develop Solid self-micro emulsifying Drug Delivery System (S-SMEDDS) of valsartan to improve its oral bioavailability. The formulations were explored on the basis of solubility, FTIR study and excipient compatibility, emulsification efficiency, particle size and zeta potential.